{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091766","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.367271+00:00","generated_at":"2026-05-31T12:54:17.285324+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FibroGen Q2 net revenue +14% to $50.6M; cuts US workforce 75% after pancreatic trial failures","bullets":["Net loss narrowed to $15.5M ($0.16/sh) from $87.7M ($0.90) YoY; revenue $50.6M (+14%).","Raising 2024 roxadustat net product revenue guidance to $135-150M; China total net sales $92.3M (+21%).","U.S. workforce cut ~75% after pamrevlumab misses endpoints in pancreatic cancer trials (PanCAN, LAPIS).","Focusing on FG-3246 ADC for mCRPC; Phase 2 combo topline expected 1H 2025, monotherapy study start 1Q 2025.","Cash, equivalents and AR $147.1M; runway into 2026; CIA approval in China 2H 2024 could trigger $10M milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091766","json":"https://secwatch.observer/filing/0000950170-24-091766.json","markdown":"https://secwatch.observer/filing/0000950170-24-091766.md","text":"https://secwatch.observer/filing/0000950170-24-091766.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017024091766/0000950170-24-091766-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017024091766/fgen-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:54:17.285324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}